1. France Stocks

  2. •

    Health technology

  3. •

    Medical specialties
SpineGuard

SpineGuard

0.08
EUR
+0.00
(-0.35%)
9.01MMarket Cap
Apr 15Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.98
0.85
1.12
1.27
1.27
1.02
0.63
0.21
0.14
0.16
0.1
0.09
0.05
- -
Basic EPS, GAAP
-0.76
-0.88
-0.7
-0.71
-0.64
-0.31
-0.06
-0.12
-0.05
-0.07
-0.1
-0.06
-0.03
- -
Free Cash Flow per Basic Share
-0.65
-0.66
-0.5
-0.69
-0.4
-0.1
0.01
-0.03
-0.04
-0.04
-0.09
-0.05
-0.02
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
1.76
1.11
0.81
0.2
-0.03
-0.06
0.04
- -
0.14
0.13
0.11
0.06
0.06
0.06
Tangible Book Value per Share
0.91
0.31
0.07
-0.5
-0.63
-0.54
-0.21
-0.14
0.03
0.02
0.03
-0.01
0.01
0.01
Basic Weighted Avg Shares
5
5
6
6
6
7
11
23
32
36
44
50
70
75
Sales/Revenue/Turnover
5
4
6
7
8
8
7
5
4
6
4
5
4
- -
Operating Margin (%)
-69.49
-102.71
-63.81
-48.68
-36.23
-14.65
-6.32
-37.84
-34.01
-27.26
-82.45
-65.89
-44.19
- -
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-4
-5
-4
-4
-4
-2
-1
-3
-2
-2
-4
-3
-2
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-77.47
-104.08
-62.26
-55.98
-50.47
-30.81
-10.04
-55.99
-39.15
-42.74
-97
-66.3
-55.03
- -
Working Capital
6
2
3
3
- -
1
-1
-4
4
3
3
- -
1
1
LT Debt
1
- -
3
6
4
5
3
1
4
3
2
1
1
1
Total Equity
9
6
5
1
- -
- -
1
- -
5
5
6
4
5
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
-49.39
-61.83
-73.85
-141.04
- -
- -
- -
- -
- -
-46.97
-74.88
-62.04
-44.1
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
1
1
1
LT Borrowings
1
1
1
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
63
73
89
Market Capitalization
13
8
9

Working Capital

EUR

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
3
3
3
Cash, Cash Equivalents & STI
1
1
2
Accounts Receivable, Net
1
1
1
Inventories
1
1
1
Total Current Liabilities
3
3
2
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-5,700.98%
-11,325.95%
40.2%
Free Cash Flow
-60.35%
30.45%
-55.03%
Net Income, GAAP
20.64%
3.56%
-32.91%
Sales/Revenue/Turnover
-3.32%
-3.29%
-19.16%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
4
2024
- -
- -
5
2025
- -
- -
4

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
-0.1
2024
- -
- -
-0.06
2025
- -
- -
-0.03

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
- -
2024
- -
- -
- -
2025
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Pierre Jérôme
Full Time Employees
13
Sector
Health technology
Industry
Medical specialties
Address
10 Cours Louis LumiEre Vincennes IF France 94300
IPO Date
Apr 29, 2013
Website
spineguard.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
SpineGuard S.A. is a French medical technology company specializing in the design, development, and commercialization of advanced surgical devices embedded with Dynamic Surgical Guidance (DSG) technology for spine surgery. Its core product portfolio includes the PediGuard range of handheld drilling devices that provide real-time, radiation-free feedback to surgeons to ensure the accurate and safe placement of pedicle screws and other spinal implants. The company also develops devices for anterior spine surgery such as the Threaded PediGuard, and is expanding its technology applications to related skeletal surgeries including dental implantology and robotic-assisted procedures through strategic industrial partnerships. In recent developments, SpineGuard has strategically partnered with US-based Omnia Medical, signing a binding term sheet for transferring its US subsidiary and extending the partnership to include the commercial launch and distribution of new products such as the PsiFGuard, a smart drilling device dedicated to sacroiliac joint fusion. The PsiFGuard received FDA clearance in 2024 and marks the company’s expansion into additional orthopedic surgical markets beyond spinal fusion. SpineGuard also completed a bond financing round to support new product deployments and obtained a European patent for an automatic bone breach detection system applicable to power drills and surgical robotics. The company has significantly increased its US revenue by 20% in 2024, driven by orders from Omnia Medical and regaining direct access to pediatric accounts formerly managed by Wishbone Medical. Founded in 2009 and headquartered in Paris, SpineGuard operates globally with a focus on markets in Europe, the United States, and ongoing registration efforts in China. The company’s technology platform is recognized for enhancing surgical safety and accuracy by reducing reliance on fluoroscopy and X-rays during implant placement. Its product ecosystem includes smart drilling devices under the PediGuard brand, the PsiFGuard device for sacroiliac fusion, and ongoing R&D initiatives to improve sensing technologies for orthopedic and skeletal surgeries. SpineGuard remains committed to driving adoption of its DSG technology through innovation, strategic partnerships, and focused geographic expansion.